MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. - Wikidata - wikimedia - TriplyDB

MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.

MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.

http://www.wikidata.org/entity/Q33651005

about

Dinosaurs and ancient civilizations: reflections on the treatment of cancer Cytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough?A novel role for BDNF-TrkB in the regulation of chemotherapy resistance in head and neck squamous cell carcinoma The Reversal Effect and Its Mechanisms of Tetramethylpyrazine on Multidrug Resistance in Human Bladder Cancer Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment.Breast cancer resistance protein (BCRP) and excision repair cross complement-1 (ERCC1) expression in esophageal cancers and response to cisplatin and irinotecan based chemotherapy.ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy Detection of circulating tumor cell subpopulations in patients with head and neck squamous cell carcinoma (HNSCC).EGFR, FLT1 and heparanase as markers identifying patients at risk of short survival in cholangiocarcinoma Current therapeutic strategies for invasive and metastatic bladder cancer.Individual profiling of circulating tumor cell composition in patients with non-small cell lung cancer receiving platinum based treatment.A Review of ERCC1 Gene in Bladder Cancer: Implications for Carcinogenesis and Resistance to Chemoradiotherapy Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) as a novel marker in T1 high-grade and T2 bladder cancer patients receiving neoadjuvant chemotherapy The interconnectedness of cancer cell signaling.Biomarkers for prognosis and treatment selection in advanced bladder cancer patients.Progress in personalizing chemotherapy for bladder cancer Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics.Biomarker development in the context of urologic cancers Circulating Tumor Cell Composition in Renal Cell Carcinoma.Co-expression of ERCC1 and Snail is a prognostic but not predictive factor of cisplatin-based neoadjuvant chemotherapy for bladder cancer Elevated STAT3 Signaling-Mediated Upregulation of MMP-2/9 Confers Enhanced Invasion Ability in Multidrug-Resistant Breast Cancer Cells.Contemporary management of muscle-invasive bladder cancer ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.JNK1/2 Activation by an Extract from the Roots of Morus alba L. Reduces the Viability of Multidrug-Resistant MCF-7/Dox Cells by Inhibiting YB-1-Dependent MDR1 Expression.Formation and repair kinetics of Pt-(GpG) DNA adducts in extracted circulating tumour cells and response to platinum treatment.Rack1 Mediates the Interaction of P-Glycoprotein with Anxa2 and Regulates Migration and Invasion of Multidrug-Resistant Breast Cancer Cells Pharmacogenomics in bladder cancer.Snail expression and outcome in T1 high-grade and T2 bladder cancer: a retrospective immunohistochemical analysis The effect and clinical consequences of hypoxia on cytochrome P450, membrane carrier proteins activity and expression.Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?Inhibitory member of the apoptosis-stimulating protein of p53 is overexpressed in bladder cancer and correlated to its progression.Overexpression of ABCC3 promotes cell proliferation, drug resistance, and aerobic glycolysis and is associated with poor prognosis in urinary bladder cancer patients.The role of phenethyl isothiocyanate on bladder cancer ADM resistance reversal and its molecular mechanism.Twist confers chemoresistance to anthracyclines in bladder cancer through upregulating P-glycoprotein.Landmarks in the treatment of muscle-invasive bladder cancer.Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer.Update in Urothelial Carcinoma: Novel Agents and Targeted Therapy.Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent.Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration

P2860

Q24628746-F5DC9026-DA68-4CEA-BF9D-1D18D707586E Q27026717-EF05D436-F5E6-431F-B2C3-6358E24D951E Q28479007-5BB108E6-1017-42D6-A978-353F8DB73B9B Q28552489-27824C14-DA18-43AB-AFE1-0E76AB3E023F Q33871764-BDD8FF70-DE42-46CE-92FE-23686CF9DDAA Q33914197-48AE72E4-7C26-406A-A34D-47EEA6F2FA5A Q33947983-C88C9C43-7054-409F-B859-36D6B3052687 Q34278209-5D76D96E-446A-4AC4-8C7B-2C47F1E06AC7 Q34640026-E0E02014-EBF4-471C-B76B-4598AC79DF45 Q34738001-B93A9652-B50F-4D3B-806A-DD1B55938C8D Q35128721-73B1675B-6F2B-4C68-BDFC-4325722FB8E4 Q35200511-86EBFB65-36CB-4980-A9B2-5D6A3FD893C0 Q35495280-90A08D8E-C62A-4891-84EF-ED43E6E0A206 Q35667815-B98B5E1A-0E5C-448B-97CF-3959A9B4791E Q35669733-3BBAC77B-FD53-47C7-A9AB-D68506E0261C Q35671292-0B05F1F8-502F-4520-A09C-90D5EF59CDBE Q35779460-99B5A972-ACBF-4887-8B69-8AEF144D65C4 Q35806000-A02A4938-13C3-48D3-976C-5C9BB1238C68 Q35906352-4F6A1388-7690-46FD-B42E-2DAE00B47FAB Q35996235-5BA36947-31C5-4518-9827-51143B6E42D2 Q36099310-F773BB71-9AE4-4574-B53D-4CE80316670F Q36247462-8DF8156C-488A-40EF-A5F1-BDAD615DE1C2 Q36389716-2B1FBCCA-B0DD-4921-BA98-51CA33C6872D Q36739002-4C2B9EFB-19E9-45BF-AC55-6883B80B8844 Q37091032-303C4CF3-3497-4ED5-96EC-3C3C83F8DBD6 Q37185747-9018A755-5422-40DB-AC04-E53F68E83B69 Q37377476-BED26C1F-E965-4E00-A231-9D8F776AB713 Q37523551-F4CFAAD6-FD62-462B-ACB3-EFF457753FCB Q37557751-C36854E2-6251-4D0C-B638-434B2318162C Q37880895-284384C3-7DFB-4DC5-AE9A-CD6952CD8DBC Q38312045-352B7A54-4DA9-4A5B-B12F-0DF0A5813D40 Q38794118-89BAF2D9-71F9-4CE7-9D4A-E4357D20CA67 Q38806337-308414EE-D5EB-4223-A46B-EDFE143ACF92 Q39180799-BE2A2A20-9975-4C7F-80E4-5ADEE3EC0586 Q39276686-E4C71652-1973-4B79-BAC9-4B8A0789F1B8 Q39413207-A8BF5385-FC43-4991-8039-C138C01FDF57 Q39459198-E24FA9E5-E476-4686-B04C-F076144FC533 Q39766258-8969D874-7968-40A0-9A55-D3FFF4EA508F Q41056921-1234F69A-1A30-4166-B06D-03647C2790E2 Q41879186-D555F541-BFC5-46FC-8CC9-54AD4391794E

P2860

MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.

http://www.wikidata.org/entity/Q33651005

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

MDR1 and ERCC1 expression pred ...... ceiving adjuvant chemotherapy.

@ast

MDR1 and ERCC1 expression pred ...... ceiving adjuvant chemotherapy.

@en

type

label

MDR1 and ERCC1 expression pred ...... ceiving adjuvant chemotherapy.

@ast

MDR1 and ERCC1 expression pred ...... ceiving adjuvant chemotherapy.

@en

prefLabel

MDR1 and ERCC1 expression pred ...... ceiving adjuvant chemotherapy.

@ast

MDR1 and ERCC1 expression pred ...... ceiving adjuvant chemotherapy.

@en

P1433

Q33651005-39DF06E2-F154-46FE-B4FE-7D6B0C92F8A0

P1476

Q33651005-EC5BD25B-D34A-4722-BCFF-B9369504E177

P2093

Q33651005-6F5C4158-D437-43AB-BE0D-CF8649F4E37D

Q33651005-796287C1-2FDA-430E-9362-3C03E8AC1087

Q33651005-7AB8E822-83B2-4530-BCB6-3683EBBB694D

Q33651005-829EF190-2DD9-44BF-85FA-A2877A484A94

Q33651005-892CC416-F52D-45C0-B798-263EC49BB494

Q33651005-B039399D-3DDC-4AEE-8A1B-CA2052110497

Q33651005-B4B0AD04-5DDD-4790-AD13-D6E2B4CC9CD8

Q33651005-B9F50031-218B-4BB3-B715-4F8014D69D78

Q33651005-D9B879F8-5253-461B-94BC-BD7B38B52C62

Q33651005-ED0B9309-89B3-4043-84CC-8BB2FA75D699

P2860

Q33651005-08E773ED-CFA9-42A2-9453-FF022B931488

Q33651005-0CF40D48-14BF-4E8D-88A8-04D5E7DDA8BC

Q33651005-0F2CCBFF-808C-4185-8EE0-A4AF4E08BC60

Q33651005-124596B2-D6F1-4968-B296-868BCA25DAE4

Q33651005-18F8BB4C-AFB0-483E-B40D-E346E3605C88

Q33651005-1EDA34BD-3540-4F6C-AD45-29BA254A6895

Q33651005-4017FE40-75EC-47BF-97DE-5403716654F0

Q33651005-7398FEEC-906C-423B-AED7-EB81E5D2A6BD

Q33651005-74B7350E-C196-4E2C-9348-4E83AB829589

Q33651005-78A9BF98-3F70-48B5-A975-1C5EF1922D49

P304

Q33651005-570EAC39-5F39-485B-B3A9-B894F4FE9634

P31

Q33651005-DCC2D50C-8B3C-41B1-BCB2-390F3B22D654

P356

Q33651005-9428849B-D4AD-4A5A-A6BB-59772EB1D689

P433

Q33651005-877FB3D2-38B9-40D3-A4E5-1695D09F7C8C

P478

Q33651005-9D1230D8-EAD3-4835-9554-9051F58085B2

P50

Q33651005-07788F89-50C4-4F5E-8CDC-BDB59F4223F6

P577

Q33651005-619EAFF4-88F8-48B8-8399-B74B648C4805

P698

Q33651005-0628EF23-B019-4BA8-A399-0F81D46F0FA1

P921

Q33651005-034D774F-3463-4381-B7BB-51C4123E34F2

P932

Q33651005-4BE487B5-9737-4F63-8A05-98CC7150DB36

P356

P1433

P1476

MDR1 and ERCC1 expression pred ...... eceiving adjuvant chemotherapy

@en

P2093

Arndt Hartmann

http://www.w3.org/2001/XMLSchema#string

Christina Leicht

http://www.w3.org/2001/XMLSchema#string

Jan Lehmann

http://www.w3.org/2001/XMLSchema#string

Kathleen D Danenberg

http://www.w3.org/2001/XMLSchema#string

Martin Schuler

http://www.w3.org/2001/XMLSchema#string

Michael Stöckle

http://www.w3.org/2001/XMLSchema#string

Peter V Danenberg

http://www.w3.org/2001/XMLSchema#string

Peter Wild

http://www.w3.org/2001/XMLSchema#string

Robert Stöhr

http://www.w3.org/2001/XMLSchema#string

Simone Bertz

http://www.w3.org/2001/XMLSchema#string

P2860

CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy

Bladder cancer: narrowing the gap between evidence and practice

Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer.

High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF.

A three-gene signature for outcome in soft tissue sarcoma.

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine.

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

Molecular manipulations of the multidrug transporter: a new role for transgenic mice.

Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome

P304

628-636

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1593/NEO.10402

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Andreas-Claudius Hoffmann

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20689757

http://www.w3.org/2001/XMLSchema#string

P921

P932

2915407

http://www.w3.org/2001/XMLSchema#string